[Lutetium-177 radiolabeled somatostatin analogs in neuroendocrine tumors]

Gonzalez L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A.
Record ID 32018001427
Authors' recommendations: CONCLUSIONS Moderate quality evidence showed that the use of 177Lu-DOTATATE in patients with well-differentiated advanced neuroendocrine tumors of the midgut (small bowel, appendix and ascending colon), with somatostatin receptor overexpression and progressed to first-line treatment might increase overall survival, progression-free survival and objective response rate. Very low-quality evidence showed that the use of Lutetium-177 radiolabeled somatostatin analogs in patients with neuroendocrine tumors of another location might present the same benefit
Project Status: Completed
Year Published: 2017
URL for published report: https://www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Neuroendocrine Tumors
  • Antineoplastic Agents
  • Octreotide
  • Organometallic Compounds
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.